Primary Sjögren syndrome that initially presented with repeated hypergammaglobulinemic purpura after prolonged sitting
A case report
Zhihua Zhou, MD, PhD∗, Weiqiang Jiang, MD, Ming Wang, MD, PhD, Yongyuan Liu, MD, Wei Zhang, MD, Manping Huang, MD, Donghui Liang, MD∗

Abstract
Rationale: Purpura is a common dermatologic manifestation in Sjögren syndrome (SS). When a patient presents with sicca symptoms, the diagnosis of SS is not difficult.

Patient concerns: Here, we reported a case of a 52-year-old Chinese woman who initially presented with nonpalpable purpura on both lower extremities, and these lesions had developed soon after prolonged sitting. In the past 2 years, she had repeated cutaneous nonpalpable purpura 4 times. She had no sicca symptoms, dry eyes, or dry mouth.

Diagnoses: Combining the laboratory findings, Schirmer test, and labial gland biopsy, primary SS was confirmed.

Interventions: The patient was placed on a trial of hydroxychloroquine (200 mg once daily).

Outcomes: The purpura on both lower extremities had faded at the sixth day after onset and at the third day after hydroxychloroquine treatment.

Lessons: These case was not easy to diagnosis primary SS because she had no sicca symptoms. A patient with primary SS who initially presented with recurrent purpura associated with prolonged sitting. Prolonged sitting had been a possible aggravating factor for the cutaneous purpura of this patient with primary SS.

Abbreviations: CT = computed tomography, HGP = hypergammaglobulinemic purpura, SS = Sjögren syndrome.

Keywords: primary Sjögren syndrome, prolonged sitting, purpura

1. Introduction
Sjögren syndrome (SS) is a chronic, systemic, autoimmune disease that mainly affects the extradigital anatomy, such as salivary and lacrimal glands. SS can be isolated (primary SS [pSS]) or associated with other autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis (secondary SS). pSS has wide clinical manifestations. Cutaneous manifestations of SS have been thoroughly reviewed.[1] Patients with SS usually report persistent sicca symptoms of dry eyes (xerophthalmia) and dry mouth (xerostomia), and other symptoms, including diverse general symptoms and cutaneous symptoms, such as purpura.[2] Here, we report a case of a 52-year-old woman who had no obvious symptoms of dry eyes and dry mouth, and who initially presented with recurrently nonpalpable purpura on both lower extremities, and these lesions had developed soon after prolonged sitting.

2. Case report
A 52-year-old Chinese woman was admitted to our hospital because of recurrent purpura on both lower extremities for 2 days (Fig. 1). In the past 2 years, she reported that similar lesions had developed 4 times after prolonged sitting. The longest time of sitting was 15 hours in an airplane, and the shortest time was 4.5 hours by high-speed rail. The purpura on both lower extremities lasted 5 to 7 days and subsided completely each time.

The rest of her medical history was not remarkable. The patient denied a history of dry eyes, dry mouth with occasional painful sores, intermittent swollen and painful lymph nodes, and perpetual nausea. She occasionally felt fatigue. She reported no history of Raynaud phenomenon, swelling of the parotid glands, swollen or joint pain, fever, headache, abdominal pain, shortness of breath, weakness, blood clots, miscarriage, or photosensitivity. On admission, her vital signs were stable, with a temperature of 36.5°C, blood pressure of 120/75 mm Hg, and pulse rate of 70/min. Except for the purpura on both lower extremities, physical examination for chest and abdomen showed no abnormalities.

Her laboratory findings at that time were significant for mild anemia, elevated antinuclear antibody, anti-SS-A/SS-B/Ro-52
antibody titers, and serum globulin of 42.1 g/L (20.2–30.0 g/L).
Serum immunofixation electrophoresis was negative. Anti-Sm/Scl-70/PM-Scl/Jo-1 antibody and anti-CENP-B/PCNA/ds-DNA/
Anu/AH/ARP/AMA-M2 antibody were negative. Detailed
laboratory results are shown in Table 1.

No malignant tumor was observed by ultrasonography and
computed tomography (CT) scan. Hepatic ultrasonography
showed steatosis in the liver. The Schirmer test showed that the
strips were wet only 2 mm in 5 minutes on each eye. Tear break-
up time was 2 seconds in each eye.

The patient underwent a minor labial gland biopsy under local
anesthesia. Histopathologic examination revealed partial atro-
phy of the salivary glands and hyperplasia of interstitial
fibrous tissue (Fig. 2A, B). There were infiltrations of many lymphocytes
and plasmacytes, and no malignant changes were observed
(Fig. 2C, D).

Based on these findings, the diagnosis of pSS was con-
firmed.

The patient was placed on atrial of hydroxychloroquine (200 mg
once daily), and the purpura on both lower extremities had faded
at the sixth day after onset and at the third day after
hydroxychloroquine treatment.

### 3. Discussion

Purpura is a common dermatologic manifestation of SS,[3] and
the most common palpable and nonpalpable purpura, which is
associated with pSS, occurs on the lower extremities.[4] This
patient’s clinical manifestation is nonpalpable purpura on both
lower extremities. The patient had no obvious symptoms of dry
eyes and dry mouth, but the diagnosis of pSS was confirmed
based on the positive findings, Schirmer test, anti-SS-A/SS-B
antibody, and biopsy.

In Chinese patients with pSS, the ratio of purpura at initial
presentation is 7.7%.[1] When this patient was confirmed as
having pSS, she had presented obvious sicca symptoms, such as

### Table 1

| Laboratory tests of the patient. | Results | Normal range |
|----------------------------------|---------|-------------|
| Urine protein                    | Negative| Negative    |
| Urine latent blood test          | Negative| Negative    |
| Urea Bence-Jones protein         | Negative| Negative    |
| White blood cells count          | 4.35 x10^12/L | 3.5–9.5 x10^12/L |
| Red blood cells count            | 3.75 x10^12/L | 3.8–5.1 x10^12/L |
| Hemoglobin                       | 111 g/L  | 115–150 g/L |
| Platelets count                  | 262 x10^12/L | 125–350 x10^12/L |
| Total bilirubin (TBil)           | 8.7 μmol/L | 5.1–20.5 μmol/L |
| Direct bilirubin (DBil)          | 1.9 μmol/L | 0–6.0 μmol/L |
| Alanine aminotransferase (ALT)   | 54 IU/L | 5–40 IU/L |
| Aspartate aminotransferase (AST) | 47 IU/L | 5–40 IU/L |
| Total protein                    | 88.1 g/L | 60.0–83.0 g/L |
| Albumin                          | 46.0 g/L | 35.0–55.0 g/L |
| Globulin                         | 42.1 g/L | 20.0–30.0 g/L |
| Prothrombin time (PT)            | 12.2 s | 11.0–15.0 s |
| Activated partial thromboplastin time (APTT) | 33.8 s | 28.0–45.0 s |
| Thrombin time (TT)               | 17.4 s | 14.0–21.0 s |
| International normalized ratio (INR) | 0.92 | 0.8–1.2 |
| Serum immunoglobulin G (IgG)     | 34.0 g/L | 7.2–16.8 g/L |
| Serum immunoglobulin A (IgA)     | 1.81 g/L | 0.6–2.8 g/L |
| Complement 3 (C3)                | 1.60 g/L | 0.85–1.93 g/L |
| Complement 4 (C4)                | 0.41 g/L | 0.12–0.36 g/L |
| Rheumatoid factor (RF)           | 374.0 IU/L | 0–30 IU/L |
| Erythrocyte sedimentation rate (ESR) | 85 mm/h | 0–37 mm/h |
| Hypersensitivity C-reactive protein (hsCRP) | 2.57 mg/L | 0.21–0.53 mg/L |
| Kappa light chain                | 7.34 g/L | 1.7–3.7 g/L |
| Lambda light chain               | 3.26 g/L | 0.9–2.1 g/L |
| Antinuclear antibody (ANA)^*      | >1:320   | <1:100      |
| Anti-SS-A antibody               | +++      | —           |
| Anti-SS-B antibody               | +        | —           |
| Anti-Ro-52 antibody              | +++      | —           |

* Antinuclear antibody (ANA) specked pattern.

---

**Figure 1.** Pictures demonstrating purpura our both extremities. (A) demonstrated the purpura on both lower extremities on the first day, (B) demonstrated purpura on the right medial malleolus at the third day, and (C) showed the purpura subsided completely at the sixth day.

**Figure 2.** Right lower labial gland biopsy. Histopathologic examination revealed a partial atrophy of the salivary glands (A) and hyperplasia of interstitial fibrous tissue (B). There were infiltrations of many lymphocytes and plasmacytes (C, D), and no malignant changes were observed (hematoxylin and eosin, ×100).
dry eyes and dry mouth. Hypergammaglobulinemic purpura (HGP) is associated with SS. Laboratory findings indicated that the patient had hypergammaglobulinemia. So, the clinical manifestation and abnormal laboratory findings indicated that this patient’s purpura was caused by hypergammaglobulinemia. In addition, abnormal liver function was also found in pSS. However, because the patient’s hepatic ultrasonography showed steatosis in the liver, we could not conclude that the patient’s abnormal liver function was caused only by pSS.

Our patient had a peculiar history of repeated presentation of the nonpalpable purpura in association with prolonged sitting. Prolonged standing can induce purpura, and the author speculated that prolonged standing increased the capillary pressure and caused purpura. In our case, prolonged sitting seemed to trigger purpura.

4. Conclusions

Thus, for patients who have only palpable and nonpalpable purpura, early diagnosis of pSS is not easy. Moreover, pSS has variable clinical manifestations, which partially explains delays in diagnosis of up to 10 years from the onset of symptoms. Therefore, it is an interesting case of pSS with HGP. This case may suggest that prolonged sitting could have potentially triggered the recurrent purpura in patients who suffered from SS with HGP. Further, it reminds the patient with pSS to engage in intermittent activity during prolonged sitting.

References

[1] Kittridge A, Routhouska SB, Korman NJ. Dermatologic manifestations of Sjogren syndrome. J Cutan Med Surg 2011;15:8–14.
[2] Cheong SH, Han YJ, Choi YW, et al. A case of Sjogren’s syndrome that presented with alcohol-induced purpura. Ann Dermatol 2010;22:99–101.
[3] Ramos-Casals M, Anaya JM, García-Carrasco M, et al. Cutaneous vasculitis in primary Sjogren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) 2004;83:96–106.
[4] Alexander EL, Provost TT. Cutaneous manifestations of primary Sjogren’s syndrome: a reflection of vasculitis and association with anti-Ro (SSA) antibodies. J Invest Dermatol 1983;80:386–91.
[5] Zhao Y, Li Y, Wang L, et al. Primary Sjogren syndrome in Han Chinese: clinical and immunological characteristics of 483 patients. Medicine (Baltimore) 2015;94:e667.
[6] Habib GS, Nashashibi M. Hypergammaglobulinemic purpura in two sisters with Sjogren’s syndrome responding to colchicine treatment. Clin Rheumatol 2004;23:170–1.
[7] Sawada Y, Kudo I, Kanazawa T, et al. Orthostatic purpura: report of two cases. Rinsho Ketsueki 1991;32:1569–73.
[8] Brito-Zerón P, Ramos-Casals M. EULAR-SS task force group. Advances in the understanding and treatment of systemic complications in Sjogren’s syndrome. Curr Opin Rheumatol 2014;26:520–7.